Chris MacDonald

Chris MacDonald

Chris MacDonald is an MBA (finance) graduate with extensive experience covering small-, mid- and large-cap companies in the U.S. and Canadian markets. Chris is interesting in uncovering long-term and deep-value opportunities for investors based on principles from the Graham-Buffett school of thought, and looks forward to bringing investors a unique fundamental-based perspective on opportunities available in today’s challenging investing environment.

His experience as a financial analyst in the past, coupled with his fervor for finding undervalued growth opportunities, contribute to his conservative, long-term investing perspective.

Recent Articles

Orphazyme Stock: 7 Things to Know About ORPH as Shares Skyrocket

Today, Orphazyme stock is on the move and is trading with extremely heavy volume, as momentum traders drive up the value of this small cap.

SPRT Stock: Why Experts Are Betting on a Bright Future for Support.com

Today, SPRT stock is on the move as various experts have chimed in on its near-term potential as a trading opportunity.

MEDS Stock: The Huge Covid-19 News Lifting Trxade Health Today

Today, MEDS stock is soaring after the company announced the launch of an application designed to be a Covid-19 passport.

ORPH Stock: Is There a Big Orphazyme Catalyst on June 17?

Today, ORPH stock is on the move, on what appears to be no real catalysts as momentum traders pile into this small cap stock.

China Crypto News: Another Province Just Cracked Down on Crypto Miners

The latest China crypto news includes yet another provincial ban on cryptocurrency mining. Here's what investors should know.